Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$11.11 USD
-0.39 (-3.39%)
Updated May 31, 2024 04:00 PM ET
After-Market: $11.10 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Sage Therapeutics, Inc. [SAGE]
Reports for Purchase
Showing records 61 - 80 ( 160 total )
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Quiet 4Q21 Call Ahead of Zuranolone Rolling NDA This Year; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
CORAL Hits Primary Endpoint But Data Raises Many More Questions Than It Answers; Reit Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
CORAL Hits Primary Endpoint; Debate Likely To Persist
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Rx for Portfolios, Part 1: Companies With Transformative Clinical Readouts Fast Approaching
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
FutureCast: SAGE-718 LUMINARY Data Arrives - On To CORAL
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Five Key Takeaways From Sage?s Third Annual FutureCast R&D Event; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
SHORELINE 50mg Data Validates Benefit But Shows That More Isn?t Always Better; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
More Of The Same (A Good Thing) - Updated SHORELINE Results
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
CORAL Trial?s Primary Endpoint Change Adds to Confusion; Reiterate Neutral, PT to $55
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Four Key Takeaways From Zuranolone Data Presentation at ECNP; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology- Investor Day Takeaways, Read Throughs
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Incremental Pipeline Update on Quiet 2Q Call; Reiterate Neutral, Price Target Down to $80
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
SKYLARK Shifts But Won''t Slow Down Zuranolone Efforts
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Zuranolone Goes Down Waterfall in a Barrel; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Going Over The WATERFALL Results - We Still Think There''s A Path Forward
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L